| Year |
Citation |
Score |
| 2024 |
Rodden DJ, Chung EH, Pittie R, Miyamoto DT. Imposter among us: field cancerization in the bladder. Translational Andrology and Urology. 13: 1319-1323. PMID 39100848 DOI: 10.21037/tau-24-8 |
0.316 |
|
| 2023 |
Miyamoto DK, Curnutt NM, Park SM, Stavropoulos A, Kharas MG, Woo CM. Design and Development of IKZF2 and CK1α Dual Degraders. Journal of Medicinal Chemistry. PMID 38085607 DOI: 10.1021/acs.jmedchem.3c01736 |
0.379 |
|
| 2023 |
Zhou Y, Börcsök J, Adib E, Kamran SC, Neil AJ, Stawiski K, Freeman D, Stormoen DR, Sztupinszki Z, Samant A, Nassar A, Bekele RT, Hanlon T, Valentine H, Epstein I, ... ... Miyamoto DT, et al. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer. Science Advances. 9: eadg2263. PMID 37992168 DOI: 10.1126/sciadv.adg2263 |
0.308 |
|
| 2020 |
Miyamoto DT, Abbosh PH, West CML, Mouw KW. Bladder preservation: Translating discovery for clinical impact in urothelial cancer. Urologic Oncology. PMID 33257220 DOI: 10.1016/j.urolonc.2020.11.021 |
0.343 |
|
| 2019 |
Fisher RR, Pleskow HM, Bedingfield K, Miyamoto DT. Noncanonical Wnt as a prognostic marker in prostate cancer: "You can't always get what you Wnt". Expert Review of Molecular Diagnostics. PMID 31814454 DOI: 10.1080/14737159.2020.1702522 |
0.306 |
|
| 2019 |
Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright JL, Dall'Era M, Douglas J, Boormans JL, van der Heijden MS, Wu CL, van Rhijn BW, et al. Molecular characterization of neuroendocrine-like bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30952638 DOI: 10.1158/1078-0432.Ccr-18-3558 |
0.348 |
|
| 2019 |
Zheng Y, Comaills V, Burr R, Boulay G, Miyamoto DT, Wittner BS, Emmons E, Sil S, Koulopoulos MW, Broderick KT, Tai E, Rengarajan S, Kulkarni AS, Shioda T, Wu CL, et al. COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. PMID 30819896 DOI: 10.1073/Pnas.1819303116 |
0.342 |
|
| 2018 |
Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, et al. A digital RNA signature of Circulating Tumor Cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discovery. PMID 30104333 DOI: 10.1158/2159-8290.Cd-18-0432 |
0.355 |
|
| 2018 |
Hwang WL, Pleskow HM, Miyamoto DT. Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. Advanced Drug Delivery Reviews. PMID 29326053 DOI: 10.1016/J.Addr.2018.01.003 |
0.353 |
|
| 2017 |
Grossman EA, Ward CC, Spradlin JN, Bateman LA, Huffman TR, Miyamoto DK, Kleinman JI, Nomura DK. Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-cancer Natural Products. Cell Chemical Biology. PMID 28919038 DOI: 10.1016/J.Chembiol.2017.08.013 |
0.584 |
|
| 2017 |
Bateman LA, Nguyen TB, Roberts AM, Miyamoto DK, Ku WM, Huffman TR, Petri Y, Heslin MJ, Contreras CM, Skibola CF, Olzmann JA, Nomura DK. Chemoproteomics-enabled covalent ligand screen reveals a cysteine hotspot in reticulon 4 that impairs ER morphology and cancer pathogenicity. Chemical Communications (Cambridge, England). PMID 28352901 DOI: 10.1039/C7Cc01480E |
0.6 |
|
| 2017 |
Roberts AM, Miyamoto DK, Huffman TR, Bateman LA, Ives AN, Heslin MJ, Akopian D, Contreras CM, Rape M, Skibola CF, Nomura DK. Chemoproteomic Screening of Covalent Ligands Reveals UBA5 as a Novel Pancreatic Cancer Target. Acs Chemical Biology. PMID 28186401 DOI: 10.1021/Acschembio.7B00020 |
0.593 |
|
| 2016 |
Comaills V, Kabeche L, Morris R, Buisson R, Yu M, Madden MW, LiCausi JA, Boukhali M, Tajima K, Pan S, Aceto N, Sil S, Zheng Y, Sundaresan T, Yae T, ... ... Miyamoto DT, et al. Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition. Cell Reports. 17: 2632-2647. PMID 27926867 DOI: 10.1016/J.Celrep.2016.11.022 |
0.318 |
|
| 2016 |
Hwang WL, Hwang KL, Miyamoto DT. The promise of circulating tumor cells for precision cancer therapy. Biomarkers in Medicine. PMID 27924634 DOI: 10.2217/Bmm-2016-0192 |
0.344 |
|
| 2016 |
Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, Nomura DK. GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity. Cell Chemical Biology. PMID 27185638 DOI: 10.1016/J.Chembiol.2016.03.017 |
0.525 |
|
| 2014 |
Hunerdosse DM, Morris PJ, Miyamoto DK, Fisher KJ, Bateman LA, Ghazaleh JR, Zhong S, Nomura DK. Chemical genetics screening reveals KIAA1363 as a cytokine-lowering target. Acs Chemical Biology. 9: 2905-13. PMID 25343321 DOI: 10.1021/Cb500717G |
0.498 |
|
| 2013 |
Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Science Translational Medicine. 5: 179ra47. PMID 23552373 DOI: 10.1126/Scitranslmed.3005616 |
0.328 |
|
| 2011 |
Miyamoto DT, Harris JR. Molecular predictors of local tumor control in early-stage breast cancer. Seminars in Radiation Oncology. 21: 35-42. PMID 21134652 DOI: 10.1016/J.Semradonc.2010.08.005 |
0.339 |
|
| 2010 |
Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America. 107: 18392-7. PMID 20930119 DOI: 10.1073/Pnas.1012539107 |
0.331 |
|
| Show low-probability matches. |